Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(11 sites)

China

Mg0033 20040, Beijing

Mg0033 20295, Changsha

Mg0033 20348, Fuzhou

Mg0033 20269, Guangzhou

Mg0033 20185, Jinan

Mg0033 20347, Jinan

Mg0033 20172, Shanghai

Mg0033 20184, Shenzhen

Mg0033 20204, Suzhou

Mg0033 20180, Wuhan

Mg0033 20349, Xuzhou SHI